Bristol-Myers Squibb: Buying the Unpriced Growth Engine Ahead of a Re-rate
BMY trades like a dividend defensive with legacy revenue fading, but cash flow, a 4.2% yield and material pipeline/collaboration wins argue for a re-rate. This trade targets a 20%+ upside over a 180 trading-day horizon while respecting balance sheet and patent risk with a tight stop.